Background: Patients with ischemic heart disease and preserved ventricular function
experience considerable morbidity and mortality despite standard medical therapy. Purpose …

As is well known, the pathogenesis of coronary artery disease (CAD) and its clinical
consequences, myocardial ischemia and infarction, are related both to atherosclerotic …

Background Angiotensin-converting–enzyme inhibitors improve the outcome among
patients with left ventricular dysfunction, whether or not they have heart failure. We assessed …

Background Angiotensin-converting-enzyme (ACE) inhibitors reduce cardiovascular
mortality and morbidity in patients with heart failure or left ventricular systolic dysfunction …

Background ACE inhibitors attenuate the detrimental effects of angiotensin II, and improve
survival and reduce morbidity in patients with acute myocardial infarction and evidence of …

Objectives. This study assessed whether treatment with a beta-adrenergic blocking agent in
addition to the use of the angiotensin-converting enzyme (ACE) inhibitor captopril decreases …

Left ventricular dysfunction can be improved with angiotensin-converting-enzyme inhibition
started 1 week after myocardial infarction or later. To see whether earlier intervention may …

Experimental evidence for the beneficial effects on heart failure of chronic treatment with
ACE inhibitors accumulated from early 1980 in experimental models of LV dysfunction …

OBJECTIVE This study was performed to assess the effect of treatment with ramipril on the
incidence of cardiac events after invasive revascularization in patients with asymptomatic …

Background: The role of angiotensin-receptor blockers (ARBs) in treating patients with
chronic heart failure and high-risk acute myocardial infarction (MI) has been controversial …